Aiham qdaisat

[Demis Lipe, MD @DemisLipe]

Emergency department use by patients who received chimeric antigen receptor T cell infusion therapy https://t.co/iPnvhtTbmg @AQdaisat @MonicaWattana @pchaftari @DocPavitra @FrontiersIn

[Cancers MDPI @Cancers_MDPI]

💠Concomitant DVT in #cancer patients with unsuspected PE increases risk of VTE recurrence. In patients with isolated incidental subsegmental PE and concomitant DVT, initiating anticoagulants if no contraindications exist is recommended💠
Enjoy reading👉 https://t.co/ETLQpRLV7s

[RPTH @RPTHjournal]

See how this decision can impact the risk of recurrent thrombosis in a recent #RPTH article by @DemisLipe @pchaftari @saichingyeung @RajhaEva @AishaAlBreiki3 @AQdaisat @CancerEDdoc
https://t.co/f3nkClFdpn

[RPTH @RPTHjournal]

.#Hemetwitter Do you anticoagulate patients with cancer who develop a catheter related thrombosis prior to line removal? This #RPTH paper looks at #VTE recurrence risk based on anticoagulation use prior to line removal. https://t.co/QRbObxkFMf
@DemisLipe @CancerEDdoc

[ISTH @isth]

VTE recurrence rate was INCREASED in individuals with catheter related thrombosis who did not receive anticoagulation prior to catheter removal. @DemisLipe @AQdaisat @RajhaEva @pchaftari @CancerEDdoc https://t.co/xLdKTbjsT2

[Aiham qdaisat @AQdaisat]

Proud to have our article receiving enough citations to be a top-cited article in JACEP Open.

[Aiham qdaisat @AQdaisat]

Another step forward in making cancer history!

[UT MD Anderson @UTMDAnderson]

The James P. Allison Institute is an ambitious effort to advance discovery, translational and clinical research to integrate immunobiology across disciplines. https://t.co/EiqE4ikgq2 @JimAllisonPhD @PamSharmaMDPhD @RKalluriMDPhD #EndCancer

[Blood Advances @BloodAdvances]

Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients https://t.co/Tq7KgwCD6p

[ACS Journal Cancer @JournalCancer]

In this @MDAndersonNews study, the authors examined the association b/w hypomagnesemia & survival in patients with #HeadAndNeckCancer who received concurrent chemoradiation w/ weekly infusions of cisplatin and/or carboplatin. https://t.co/Yk9PG5PIPP

CC: @RobertFerrisMD
#HNCSM